Drug intelligence / Profile preview

LC302

Development stage: Preclinical
Lead developer: Zhejiang Longcharm Bio-Tech Pharma
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies

Overview

LC302 is a preclinical-stage nucleic acid delivery platform developed by Zhejiang Longcharm Bio-Tech Pharma. It utilizes a novel transfection technology designed to facilitate the intracellular delivery of nucleic acids, such as mRNA or DNA, for therapeutic applications. While specific disease indications and molecular targets have not been publicly disclosed, the platform is part of the company's broader focus on advanced delivery systems, which includes other technologies like SORT (Selective Organ Targeting). LC302 aims to enhance the efficiency and safety profile of gene-based therapies by optimizing the transfection process.

Beyond the preview

Go deeper on LC302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC302.

Explore the full profile